SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.68-2.4%Dec 12 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (26892)5/16/2008 7:41:41 PM
From: Gary Mohilner   of 52153
 
Biomavn,

I don't know if you're still following IMGN or what's happening in the T-DM1 Trial being conducted by DNA, but if you check the ASCO Abstracts you'll find that in the weekly dosing trial which is dose escalating 4 of 7, presumedly the four having the higher dosages, all had Partial Responses, not confirmed because they haven't been in the trial long enough.

If you check the Clinical Trial database you'll also find that DNA's expanding the trials dramatically with two new Phase II trials intended to broaden the application before officially announcing a Pivotal Trial. A scientist at DNA did say they'd be going Pivotal at the presentation he made early yesterday, but the official word from the person from their IR group speaking at the BofA Conference was using the corporate line, they'll make a Go/No Go decision later this year. Even a blind man could see that this drug will get a Pivotal Trial, with the relationship they seem to have with the FDA, it could be a very short trial.

Gary
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News